Skip to content
MOMOMO999

Drawing based on the label description. No photo yet.

“40 mg/12.5 mg Light orange, oval, film-coated, biconvex tablets, debossed with "MO" on one side, and "9" on other side, free from physical defects”

MO 9 pill

Pill with imprint MO 9 is orange, oval, 15 mm and has been identified as Olmesartan Medoxomil-Hydrochlorothiazide 40 mg / 12.5 mg. It is used for high blood pressure. It is supplied by Novadoz Pharmaceuticals LLC.

Olmesartan Medoxomil-Hydrochlorothiazide 40 mg / 12.5 mg

Imprint
MO 9
Strength
Olmesartan Medoxomil 40 mg / Hydrochlorothiazide 12.5 mg
Used for
High blood pressure
Color
Orange
Shape
Oval
Size
15 mm
Score
No score line
Form
Tablet, film coated
Manufacturer
Novadoz Pharmaceuticals LLC
NDC
72205-148, 72205-148-30, 72205-148-90, 72205-148-99

Source: the official drug label on DailyMed (US National Library of Medicine). Last checked .

Report a mistake

Please do not include personal health information. For questions about your medicine, ask a pharmacist.

All Olmesartan Medoxomil-Hydrochlorothiazide pills and guides

What is Olmesartan Medoxomil-Hydrochlorothiazide used for?

Olmesartan Medoxomil-Hydrochlorothiazide is used for high blood pressure.

Official uses from the US prescribing label

BENICAR HCT (olmesartan medoxomil and hydrochlorothiazide) is indicated for the treatment of hypertension, to lower blood pressure. BENICAR HCT is not indicated for the initial therapy of hypertension.

Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with BENICAR HCT.

Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).

Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly.

Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal.

Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy.

BENICAR HCT may be used alone, or in combination with other antihypertensive drugs.

From the FDA-approved label on DailyMed (published Jul 15, 2026).

Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.

Is this your pill? Check every detail

  • One side shows MO and the other side shows 9.
  • It is orange, oval, 15 mm.
  • Its score line and coating match the details on this page.
  • It came from a pharmacy package that names the same drug.

Ingredients

Active: Olmesartan Medoxomil, Hydrochlorothiazide

Inactive: Hydroxypropyl Cellulose (110000 Wamw), Low-Substituted Hydroxypropyl Cellulose (11% Hydroxypropyl, 130000 Mw), Stearic Acid, Microcrystalline Cellulose, Talc, Titanium Dioxide, Ferric Oxide Red, Ferric Oxide Yellow, Lactose Monohydrate, Hypromellose 2910 (6 Mpa.s)

Pills that look similar but are different drugs

Same color and shape, different medicine. This is why the imprint matters.

Other Olmesartan Medoxomil-Hydrochlorothiazide pills